Anal cancer : leading the way
Menée à partir des données d'un essai de phase III incluant 940 patients atteints d'un carcinome épidermoïde de l'anus traité par chimioradiothérapie, cette étude analyse le délai optimal avant évaluation de la réponse tumorale
More than 40 years ago, anal cancer researchers provided one of the most important contributions to the field of gastrointestinal oncology.1 Norman Nigro's observation of complete pathological remission in two patients and clinical remission in one patient after neoadjuvant chemoradiotherapy founded the modern management of anal cancer.1 Since this seminal publication, organ preservation became the standard of care and is now indisputable among patients with anal carcinoma with complete clinical response to neoadjuvant chemoradiotherapy.
The Lancet Oncology , commentaire en libre accès, 2016